19 July 2021 Davies Collison Cave
The New Zealand Patent Office (
IPONZ)
has traditionally applied a hardline approach to double patenting,
particularly in relation to parent-divisional claim overlap.
However, IPONZ has now issued its first decision on double
patenting under the 2013 Act in
Oracle), heralding a relaxing of the
approach to the assessment of double patenting. As a result of this
decision, it is likely that IPONZ will only raise double patenting
objections where a claim in a divisional has substantially the same
scope as a claim in its parent.
Relevant provisions
For applications filed under the 2013 Act, i.e., having an
„Diskriminierung österreichischer Händler muss ein Ende haben
elektro.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elektro.at Daily Mail and Mail on Sunday newspapers.
Temmel, Seywald & Partner feiern 30 Jahre - Perspektivenreiche und branchenübergreifende Kommunikationsberatung
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
PreveCeutical Medical Inc.: PreveCeutical Provides Corporate Update
Vancouver, British Columbia (Newsfile Corp. - May 31, 2021) -
PreveCeutical Medical Inc. (the Company or PreveCeutical ) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pleased to provide the following update.
The Company s highest priority is to create shareholder value through the development and commercialization of products and delivery technology.
The Company has partnered with UniQuest Pty Limited and the University of Queensland through its Australian subsidiary, PreveCeutical (Australia) Pty Ltd, to conduct research and development. The Company is very pleased with the positive outcome from the successful completion of the following programs:
Stabilization of Blue Scorpion Venom was completed in October 2019.